Scarica l'app Stockscreener
34.76
0.91%
0.23
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$34.53
Aprire:
$33.99
Volume 24 ore:
946.77K
Relative Volume:
0.43
Capitalizzazione di mercato:
$3.11B
Reddito:
$333.87M
Utile/perdita netta:
$-169.00M
Rapporto P/E:
-17.04
EPS:
-2.04
Flusso di cassa netto:
$-157.30M
1 W Prestazione:
+16.89%
1M Prestazione:
+41.42%
6M Prestazione:
+64.75%
1 anno Prestazione:
+92.51%
Intervallo 1D:
$33.58
$36.15
Intervallo di 1 settimana:
$29.49
$36.15
Portata 52W:
$12.91
$36.15
Travere Therapeutics Inc Stock (TVTX) Company Profile
Nome
Travere Therapeutics Inc
Settore
Industria
Telefono
888-969-7879
Indirizzo
3611 VALLEY CENTRE DR, SAN DIEGO
Confronta TVTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
34.84 | 3.09B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.74 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.83 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.14 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
842.83 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.38 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-31 | Reiterato | Citigroup | Buy |
| 2025-06-11 | Reiterato | Citigroup | Buy |
| 2025-06-11 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-09 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-03-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-12-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-20 | Iniziato | Citigroup | Neutral |
| 2023-09-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Ripresa | Evercore ISI | Outperform |
| 2023-07-21 | Iniziato | JP Morgan | Overweight |
| 2023-06-07 | Ripresa | Piper Sandler | Neutral |
| 2023-05-22 | Iniziato | TD Cowen | Outperform |
| 2023-05-05 | Aggiornamento | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-21 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-12-14 | Iniziato | Stifel | Hold |
| 2022-12-05 | Iniziato | Wells Fargo | Overweight |
| 2022-09-21 | Iniziato | Bryan Garnier | Sell |
| 2022-07-14 | Ripresa | Canaccord Genuity | Buy |
| 2022-03-31 | Iniziato | Piper Sandler | Overweight |
| 2022-02-28 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-26 | Downgrade | Wedbush | Outperform → Neutral |
Mostra tutto
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
How Travere Therapeutics Inc. stock compares to industry benchmarks2025 Analyst Calls & High Return Stock Watch Alerts - newser.com
168,000 Shares in Travere Therapeutics, Inc. $TVTX Bought by Hussman Strategic Advisors Inc. - MarketBeat
Can Travere Therapeutics Inc. stock outperform in 2025 bull marketWeekly Trend Summary & Risk Controlled Daily Trade Plans - newser.com
Real time scanner hits for Travere Therapeutics Inc. explainedPortfolio Performance Summary & Free Fast Gain Swing Trade Alerts - newser.com
What makes Travere Therapeutics Inc. stock attractive to growth fundsRecession Risk & Weekly High Return Forecasts - newser.com
How geopolitical tensions affect Travere Therapeutics Inc. stockIPO Watch & Long-Term Investment Growth Plans - newser.com
Travere Therapeutics (TVTX) Climbs 25% on Impressive Earnings - MSN
Does Travere Therapeutics Inc. show high probability of reboundJuly 2025 Short Interest & Low Risk High Win Rate Picks - newser.com
Detecting support and resistance levels for Travere Therapeutics Inc.July 2025 Patterns & Reliable Momentum Entry Alerts - newser.com
Will Travere Therapeutics Inc. stock gain from strong economyJuly 2025 Momentum & Consistent Profit Alerts - newser.com
Can Travere Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Market Mood & Advanced Technical Analysis Signals - newser.com
Results: Travere Therapeutics, Inc. Exceeded Expectations And The Consensus Lifted Next Year's Outlook - Yahoo Finance
What recovery options are there for Travere Therapeutics Inc.Take Profit & Weekly Breakout Stock Alerts - newser.com
Can Travere Therapeutics Inc. stock hit analyst price targetsJuly 2025 PostEarnings & Safe Entry Trade Reports - newser.com
Cantor Fitzgerald Issues Negative Estimate for TVTX Earnings - MarketBeat
Will Travere Therapeutics Inc. stock outperform international peersEarnings Growth Summary & Weekly Hot Stock Watchlists - newser.com
What momentum shifts mean for Travere Therapeutics Inc.July 2025 Summary & Accurate Technical Buy Alerts - newser.com
How moving averages guide Travere Therapeutics Inc. tradingMarket Performance Summary & Precise Swing Trade Alerts - newser.com
Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook - MSN
What indicators show strength in Travere Therapeutics Inc.July 2025 Institutional & Long-Term Investment Growth Plans - newser.com
Pattern recognition hints at Travere Therapeutics Inc. upside2025 Market Trends & Community Consensus Stock Picks - newser.com
When is the best time to exit Travere Therapeutics Inc.CEO Change & Free High Return Stock Watch Alerts - newser.com
Travere Therapeutics Stock (TVTX) Opinions on Q3 Earnings Surge - Quiver Quantitative
Jennison Associates LLC Sells 80,602 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics Reports Strong Q3 2025 Growth - MSN
10 Stocks With Easy 20-40% Gains - Insider Monkey
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2025 Earnings Call Transcript - Insider Monkey
TD Cowen Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
Why Travere Therapeutics Inc. stock could outperform in 2025Market Trend Report & Reliable Price Breakout Alerts - newser.com
Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
A Look at Travere Therapeutics's Valuation Following Strong Q3 Profit and FILSPARI Momentum - Yahoo Finance
Travere Therapeutics (NASDAQ:TVTX) Reaches New 1-Year High Following Earnings Beat - MarketBeat
Travere Therapeutics (TVTX) Is Up 25.3% After FILSPARI Drives Q3 Profit Turnaround and Global Milestone - Yahoo Finance
Travere Therapeutics stock hits 52-week high at 33.66 USD By Investing.com - Investing.com Australia
Travere Therapeutics Inc (TVTX) Stock Price, Trades & News - GuruFocus
TD Cowen Maintains Travere Therapeutics (TVTX) Buy Recommendation - MSN
Travere Therapeutics (TVTX): Unprofitable But Forecast 67% Annual Earnings Growth Challenges Bearish Narratives - Yahoo Finance
TD Cowen Raises Price Target for Travere Therapeutics (TVTX) to $40 | TVTX Stock News - GuruFocus
Travere Therapeutics’ Strong Quarter and Future Prospects - TipRanks
Travere Therapeutics Delivers Growth As FILSPARI Drives Profits - Finimize
Eric Dube Sells 92,872 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $79,860.00 in Stock - MarketBeat
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CEO Sells 27,128 Shares of Stock - MarketBeat
Travere signals readiness for rapid FILSPARI launch in FSGS as Q3 2025 revenue hits $164.9M - MSN
Travere Therapeutics Inc Azioni (TVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.85%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):